# US 2015/0177253 A1 · Tumor suppressor designated ts10q23.3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0177253 A1
- Document ID: US20150177253A1
- Status: Published application
- Kind: A1
- Application number: 14/618,861
- Filed: 2015-02-10
- Published: 2015-06-25
- Earliest claimed: 1997-01-30
- Assignees: Board of Regents, The University of Texas System; Myriad Genetics, Inc.
- Applicants: Board of Regents, The University of Texas System; Myriad Genetics, Inc.
- Inventors: Peter Steck; Mark Pershouse; Samar A. Jasser; Alfred W.K. Yung; Sean V. Tavtigian
- Web page: https://patentgrep.com/patent/US20150177253A1

## CPC

- G01N 33/57595: {involving intracellular compounds}
- C07K 14/4703: {Inhibitors; Suppressors}
- C12N 9/16: acting on ester bonds (3.1)
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57555: of the prostate
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2799/021: for the expression of a heterologous nucleic acid
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q 2600/172: Haplotypes
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.

## Claims

### Claim 1

A method of determining the stage of cancer comprising the steps of (i) obtaining a sample from a subject; and (ii) determining in cells of the sample the amount of a polypeptide whose amino acid sequence comprises at least 30 contiguous amino acids of SEQ ID NO:2.

### Claim 2

A method of predicting tumor metastasis comprising the steps of (i) obtaining a sample from a subject; and (ii) determining in cells of the sample the amount of a polypeptide whose amino acid sequence comprises at least 30 contiguous amino acids of SEQ ID NO:2.

### Claim 3 (depends on 1)

The method of claim 1, wherein said cancer is chosen from the group consisting of brain, lung, liver, spleen, kidney, lymph node, small intestine, pancreas, blood cells, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow and blood cancer. In preferred embodiments, the cancer is prostate cancer or breast cancer.

### Claim 4 (depends on 2)

The method of claim 2, wherein said cancer is chosen from the group consisting of brain, lung, liver, spleen, kidney, lymph node, small intestine, pancreas, blood cells, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow and blood cancer. In preferred embodiments, the cancer is prostate cancer or breast cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein said cancer is a brain cancer.

### Claim 6 (depends on 5)

The method of claim 5, wherein the stage is distinguished between low grade and glioma.

### Claim 7 (depends on 5)

The method of claim 5, wherein said cancer is a glioma.

### Claim 8 (depends on 2)

The method of claim 2, wherein said cancer is a brain cancer.

### Claim 9 (depends on 7)

The method of claim 7, wherein said cancer is a glioma.

### Claim 10 (depends on 1)

The method of claim 1, wherein said cancer is prostate cancer.

### Claim 11 (depends on 2)

The method of claim 2, wherein said cancer is prostate cancer.

### Claim 12 (depends on 1)

The method of claim 1, wherein said sample is a solid tissue sample.

### Claim 13 (depends on 2)

The method of claim 2, wherein said sample is a solid tissue sample.

### Claim 14 (depends on 1)

The method of claim 1, wherein said sample is a fluid sample.

### Claim 15 (depends on 2)

The method of claim 2, wherein said sample is a fluid sample.

### Claim 16 (depends on 1)

The method of claim 1, wherein said determining step comprises contacting said sample with an antibody that binds immunologically to said protein.

### Claim 17 (depends on 2)

The method of claim 2, wherein said determining step comprises contacting said sample with an antibody that binds immunologically to said protein.

### Claim 18 (depends on 16)

The method of claim 16, wherein said determining step comprises an ELISA.

### Claim 19 (depends on 17)

The method of claim 17, wherein said determining step comprises an ELISA.

### Claim 20 (depends on 2)

The method of claim 2, wherein said cancer is distinguished as metastatic or non-metastatic.
